JP7629394B2 - リウマチ性疾患の治療に使用するためのコバーシン - Google Patents

リウマチ性疾患の治療に使用するためのコバーシン Download PDF

Info

Publication number
JP7629394B2
JP7629394B2 JP2021513344A JP2021513344A JP7629394B2 JP 7629394 B2 JP7629394 B2 JP 7629394B2 JP 2021513344 A JP2021513344 A JP 2021513344A JP 2021513344 A JP2021513344 A JP 2021513344A JP 7629394 B2 JP7629394 B2 JP 7629394B2
Authority
JP
Japan
Prior art keywords
seq
sequence
protein
treatment
ltb4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021513344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500389A (ja
JP2022500389A5 (https=
Inventor
ナン，マイルズ
ラスター，アンドリュー
斉重 宮部
Original Assignee
ヴォリューション イミュノ ファーマシューティカルズ エスエイ
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴォリューション イミュノ ファーマシューティカルズ エスエイ, ザ ジェネラル ホスピタル コーポレイション filed Critical ヴォリューション イミュノ ファーマシューティカルズ エスエイ
Publication of JP2022500389A publication Critical patent/JP2022500389A/ja
Publication of JP2022500389A5 publication Critical patent/JP2022500389A5/ja
Application granted granted Critical
Publication of JP7629394B2 publication Critical patent/JP7629394B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2021513344A 2018-09-10 2019-09-10 リウマチ性疾患の治療に使用するためのコバーシン Active JP7629394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729068P 2018-09-10 2018-09-10
US62/729,068 2018-09-10
PCT/EP2019/074101 WO2020053206A1 (en) 2018-09-10 2019-09-10 Coversin for use in the treatment of rheumatic diseases

Publications (3)

Publication Number Publication Date
JP2022500389A JP2022500389A (ja) 2022-01-04
JP2022500389A5 JP2022500389A5 (https=) 2022-09-09
JP7629394B2 true JP7629394B2 (ja) 2025-02-13

Family

ID=67988965

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513344A Active JP7629394B2 (ja) 2018-09-10 2019-09-10 リウマチ性疾患の治療に使用するためのコバーシン

Country Status (4)

Country Link
US (2) US20220047673A1 (https=)
EP (1) EP3849588A1 (https=)
JP (1) JP7629394B2 (https=)
WO (1) WO2020053206A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
GB202218084D0 (en) * 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511632A (ja) 2008-02-05 2011-04-14 ナチュラル・エンバイロンメント・リサーチ・カウンシル エイコサノイドによって媒介される疾患及び症状の治療
JP2017522857A (ja) 2014-02-20 2017-08-17 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 補体成分ｃ５抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69534701T2 (de) * 1994-09-23 2006-10-19 Alexion Pharmaceuticals, Inc., Cheshire Verfahren zur behandlung von entzündlichen gelenkerkrankungen
EP1629098B1 (en) 2003-06-02 2009-04-01 Varleigh Limited Complement inhibitors from ticks
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
PL2061501T3 (pl) 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
JP5840623B2 (ja) 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるｅｖ５７６
EP2978451B1 (en) * 2013-03-29 2019-11-27 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CA2988313A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
US11730792B2 (en) * 2017-04-21 2023-08-22 Volution Immuno Pharmaceuticals Sa Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511632A (ja) 2008-02-05 2011-04-14 ナチュラル・エンバイロンメント・リサーチ・カウンシル エイコサノイドによって媒介される疾患及び症状の治療
JP2017522857A (ja) 2014-02-20 2017-08-17 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 補体成分ｃ５抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUHN, Nadine et al.，PASylated Coversin, a C5-Specific Complement Inhibitor with Extended Pharmacokinetics, Shows Enhanced Anti-Hemolytic Activity in Vitro，Bioconjugate Chemistry，2016年09月06日，Vol. 27，p. 2359-2371，DOI: 10.1021/acs.bioconjchem.6b00369

Also Published As

Publication number Publication date
JP2022500389A (ja) 2022-01-04
US20250195612A1 (en) 2025-06-19
US20220047673A1 (en) 2022-02-17
WO2020053206A1 (en) 2020-03-19
EP3849588A1 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
JP7600278B2 (ja) 自己免疫性水疱症の治療のためのコバーシン
US20250195612A1 (en) Coversin for use in the treatment of rheumatic diseases
ES2906632T3 (es) Inhibidor del complemento ornithodoros moubata para uso en el tratamiento de enfermedad aguda de injerto versus huésped
EA029470B1 (ru) Способ стимулирования формирования защитного иммунитета против норовируса
KR20220058585A (ko) 치료용 융합 단백질
US20220370556A1 (en) Method of Treatment
JPH09505282A (ja) レトロウイルススーパー抗原、スーパー抗原ペプチド及び使用方法
Garcia et al. Suppression of Plasmodium MIF-CD74 signaling protects against severe malaria
WO2023020623A1 (zh) 用于预防或治疗冠状病毒感染的融合蛋白、Spike蛋白纳米颗粒及其应用
US20220211810A1 (en) Method of Treatment
JP2023052387A (ja) リウマチ関節炎治療用ペプチド及びその用途
WO1994002606A1 (en) Inhibition of retroviral expression by interferon-induced cellular genes and proteins
WO2021209636A1 (en) 28 kda gst proteins from schistosoma for the treatment of vasculitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210430

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230620

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250131

R150 Certificate of patent or registration of utility model

Ref document number: 7629394

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150